Curing Disease Not a “Sustainable Business Model,” Goldman Sachs Analysts Say

Curing disease not a “sustainable business model,” Goldman Sachs analysts say

The potential to deliver “one shot cures” is one of the most attractive aspects of gene therapy, genetically engineered cell therapy, and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies… While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.